Dual-action cancer-killing virus developed by Oxford scientists

Dual-action cancer-killing virus developed by Oxford scientists

  • November 19, 2018
Table of Contents

Dual-action cancer-killing virus developed by Oxford scientists

Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune syste The virus targets carcinomas, which are the most common type of cancer and start in cells in the skin or tissues that line or cover internal organs. A microscope image of a human colorectal adenocarcinoma showing the fibroblasts (brown) surrounding the cancer cells (blue), protecting them from the immune system (PA/Medical Research Council).

Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system and supplying it with growth factors and nutrients. Researchers at the University of Oxford said it is the first time cancer-associated fibroblasts within solid tumours have been specifically targeted in this way. They believe if further safety testing is successful, the dual-action virus – which they have tested in human cancer samples and in mice – could be tested in humans with carcinomas as early as next year.

Currently, any therapy that kills the “tricked” fibroblast cells may also kill fibroblasts throughout the body – for example in the bone marrow and skin – and cause toxicity.

Source: co.uk

Share :
comments powered by Disqus

Related Posts

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

A ‘ground-breaking’ drug that helps people with diabetes re-grow insulin-making cells has been developed. About 19,000 people live with Type 1 of the condition in Wales and 90% have less than 5% of these cells left. This means they have to inject insulin

Read More
Alphabet unit halts glucose-detecting contact lens project

Alphabet unit halts glucose-detecting contact lens project

Alphabet Inc’s life sciences division Verily said on Friday that it was putting on hold one of its oldest and highest-profile projects, a smart contact lens designed to help monitor sugar levels. The project, started in 2014, aimed to help diabetics better manage their blood sugar levels by embedding sensors on a contact lens to monitor the glucose levels in their tears. In a blog update, Verily cited here insufficient consistency in the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device.

Read More